Horizon Pharma (NASDAQ:HZNP) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.15, Briefing.com reports. The firm had revenue of $325.30 million for the quarter, compared to analysts’ expectations of $311.84 million. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. The company’s revenue was up 19.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.26 EPS. Horizon Pharma updated its FY 2018 guidance to EPS.
NASDAQ:HZNP opened at $21.97 on Friday. The company has a quick ratio of 1.63, a current ratio of 1.70 and a debt-to-equity ratio of 2.19. The firm has a market capitalization of $3.22 billion, a PE ratio of 18.62, a P/E/G ratio of 1.23 and a beta of 1.29. Horizon Pharma has a one year low of $12.55 and a one year high of $23.38.
HZNP has been the topic of several research analyst reports. Jefferies Financial Group increased their price target on Horizon Pharma from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Cowen reissued a “buy” rating and set a $25.00 price target on shares of Horizon Pharma in a report on Thursday, August 9th. Piper Jaffray Companies reissued a “buy” rating and set a $25.00 price target on shares of Horizon Pharma in a report on Thursday, August 9th. Mizuho reissued a “buy” rating and set a $18.00 price target on shares of Horizon Pharma in a report on Wednesday, August 8th. Finally, Cantor Fitzgerald set a $21.00 price target on Horizon Pharma and gave the company a “buy” rating in a report on Wednesday, August 8th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $23.58.
Large investors have recently bought and sold shares of the company. First Quadrant L P CA increased its stake in shares of Horizon Pharma by 189.1% in the 3rd quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 4,001 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Horizon Pharma by 74.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 3,877 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in Horizon Pharma in the 2nd quarter worth $172,000. Strs Ohio increased its stake in Horizon Pharma by 74.2% in the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 4,600 shares in the last quarter. Finally, ARP Americas LP purchased a new stake in Horizon Pharma in the 3rd quarter worth $229,000. Hedge funds and other institutional investors own 87.24% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Horizon Pharma (HZNP) Releases Quarterly Earnings Results, Beats Estimates By $0.15 EPS” was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/11/10/horizon-pharma-hznp-releases-quarterly-earnings-results-beats-estimates-by-0-15-eps.html.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Read More: Stock Symbols and CUSIP Explained
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.